Loading…
Contact Information

605, SGH,
Vaishali Nagar, Jaipur, Rajasthan - 302021

We're Available 24/7. Call Now.

Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (SP-02, hereinafter DARVIAS®) has been launched today in Japan for use in relapsed or refractory Peripheral T-Cell Lymphoma. DARVIAS® will be commercialized by Nippon Kayaku Co., Ltd. (TOKYO:4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220822005303/en/

SHARE:

NewsOnFloor

NewsOnFloor Staff's knowledge of Bollywood film industry is tremendous and their writing attracts all the cinema lovers. Team follows everything which is happening on the bollywood street .

Leave A Reply

Your email address will not be published. Required fields are marked *